Published: May 29, 2024 By Tristan Manalac
Pictured: Doctor holding up a lung x-ray/iStock, utah778
Insmed on Tuesday unveiled topline data from the Phase III ASPEN study demonstrating that its investigational DPP1 blocker brensocatib could…
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
MyHeritage Introduces Ancient Origins: Advanced DNA Analysis That Traces Origins Back 10,000 Years
TEL AVIV, Israel & LEHI, Utah–(BUSINESS WIRE)– #MyHeritage–MyHeritage Introduces Ancient Origins: Advanced DNA Analysis That Traces Origins Back 10,000 Years Click here to view original post Click Here to Publish/Feature Your Company or Product News […]
SocialClimb Secures $8.5 Million in Growth Funding from Spring Capital and Resolve Growth Partners
LEHI, Utah, Nov. 8, 2022 /PRNewswire/ — SocialClimb, a leading Software-as-a-Service Healthcare Marketing Platform, announced today that they raised $8.5 million of growth capital from Spring Capital Partners and Resolve Growth Partners to further accelerate […]
Canary Speech Named to TIME’s List of the World’s Top HealthTech Companies 2025
PROVO, Utah, Oct. 1, 2025 /PRNewswire/ — Canary Speech, the leading AI-powered voice biomarker health tech company, has been included in the first edition of the World’s Top HealthTech Companies 2025. This prestigious award is […]
